Article thumbnail

Rapamycin potentiates cytotoxicity by docetaxel possibly through downregulation of Survivin in lung cancer cells

By Huiyan Niu, Jiahe Wang, Hui Li and Ping He
Topics: Research
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:3065416
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2006). A: Expression of the apoptosis inhibitor protein Survivin in primary laryngeal carcinoma and cervical lymph node metastasis. Anticancer Res
  2. (2008). AA: Advances in targeting the Ras/Raf/MEK/Erk mitogenactivated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res
  3. (2004). al: An IAP-IAP complex inhibits apoptosis.
  4. (2006). al: mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res
  5. (2000). al: Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood
  6. (1998). Altieri DC: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature
  7. (2007). Altieri DC: Regulation of survivin expression by IGF-1/mTOR signaling. Oncogene
  8. (2002). Belani CP: Taxanes for advanced non-small cell lung cancer. Expert Opin Pharmacother
  9. (2001). BH: An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry
  10. (2008). Budman DR: In-vitro synergism of m-TOR inhibitors, statins, and classical chemotherapy: potential implications in acute leukemia. Anticancer Drugs
  11. (2006). Cantley LC: Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature
  12. (2005). DM: An expanding role for mTOR in cancer. Trends Mol Med
  13. (2007). DM: Defining the role of mTOR in cancer. Cancer Cell
  14. (2007). Docetaxel-induced apoptosis of human melanoma is mediated by activation of c-Jun NH2-terminal kinase and inhibited by the mitogen-activated protein kinase extracellular signal-regulated kinase 1/2 pathway. Clin Cancer Res
  15. (2005). E: MTOR-targeted therapy of cancer with rapamycin derivatives. Annals of Oncology
  16. (1998). Effect of bryostatin 1 on taxol-induced apoptosis and cytotoxicity in human leukemia cells (U937). Biochem Pharmacol
  17. (2009). et al: Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as secondline treatment of advanced non-small-cell lung cancer.
  18. (2007). et al: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
  19. (2010). et al: Treating triple-negative breast cancer by a combination of rapamycin and cyclophosphamide: an in vivo bioluminescence imaging study.
  20. (2010). Expression profile of RhoGDI2 in lung cancers and role of RhoGDI2 in lung cancer metastasis. Oncol Rep
  21. (2008). Gambogic acid, a potent inhibitor of survivin, reverses docetaxel resistance in gastric cancer cells. Cancer Lett
  22. (2006). Hershko DD: The mTOR inhibitor rapamycin down-regulates the expression of the ubiquitin ligase subunit Skp2 in breast cancer cells. Breast Cancer Res
  23. (2010). Huang B: Rapamycin inhibits lung metastasis of B16 melanoma cells through down-regulating alphav integrin expression and up-regulating apoptosis signaling. Cancer Sci
  24. (2006). IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes.
  25. (2009). Khuri FR: The role of the taxanes in the treatment of older patients with advanced stage non-small cell lung cancer. Oncologist
  26. (2004). MericBernstam F: Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res
  27. (2007). Orntoft TF: Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin Cancer Res
  28. (2010). Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer. Cancer
  29. (2004). PJ: The TOR pathway: A target for cancer therapy. Nature Reviews Cancer
  30. (2005). Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways. Mol Cancer Ther
  31. (1998). Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability.
  32. (2004). Rassidakis GZ: Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma.
  33. (2002). RB: Inhibition of phosphatidylinositol 3’-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res
  34. (2003). Reed JC: HBXIP functions as a cofactor of survivin in apoptosis suppression.
  35. (1999). RS: Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochem Biophys Res Commun
  36. (2005). S: Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Cancer Res
  37. (2009). Shamsili S: Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer.
  38. (1994). SL: A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature
  39. (2002). SN: Mechanisms which mediate the antiapoptotic effects of angiopoietin-1 on endothelial cells. Microvasc Res
  40. (2006). Survivin as a prognostic factor for osteosarcoma patients. Acta Histochem Cytochem
  41. (2007). Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients.
  42. (2003). Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene
  43. (2005). Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells. Leukemia
  44. (2009). Syrigos KN: The role of mTOR in the management of solid tumors: an overview. Cancer Treat Rev
  45. (2005). Takami T: Expression of survivin and of antigen detected by a novel monoclonal antibody, T332, is associated with outcome of diffuse large B-cell lymphoma and its subtypes. Pathol Int
  46. (2010). Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene
  47. (2007). Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene
  48. (2005). The Akt-mTOR tango and its relevance to cancer. Cancer Cell
  49. (2001). The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med
  50. (2002). The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal
  51. (2008). Wacheck V: mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo. Anticancer Res
  52. (2006). Weiss WA: A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell
  53. (2005). WK: Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline. Lung Cancer